| Literature DB >> 22761487 |
Robert J Tinnion1, Nicholas D Embleton.
Abstract
Alkaline phosphatase (ALP) is regularly measured in clinical practice. Changes in serum levels are observed in a number of clinical conditions. In neonatology, it has been proposed as a useful marker for both a diagnosis and an indication of the severity of metabolic bone disease (MBD) in infants born preterm. Nutritional practices, aimed at reducing the occurrence or severity of MBD, have led to ALP being proposed as a stand-alone means of monitoring treatment. The current evidence does not support this use: ALP only achieves usefulness in a diagnostic and monitoring capacity when combined with other serum and imaging techniques.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22761487 DOI: 10.1136/archdischild-2012-301633
Source DB: PubMed Journal: Arch Dis Child Educ Pract Ed ISSN: 1743-0585 Impact factor: 1.309